RNA Quality for RT-qPCR: RIN Scores, Degradation, and When to Proceed Anyway
The Bioanalyzer says RIN 5.8 and your samples cost a month of cell culture to make. Re-extract or proceed? The honest answer: there is no single RNA quality RIN score cutoff for qPCR. The right number depends on amplicon length, target abundance, and sample replaceability. This post walks the decision by RIN range so you can pick a defensible path and document it.
What RIN actually measures
The RNA Integrity Number is a 1–10 score from the Agilent 2100 Bioanalyzer. It replaces the older 28S:18S ratio with a Bayesian model fit to the full electrophoretic trace — ribosomal peak heights, the fast region, the inter-region, and degradation products (Schroeder et al. 2006, BMC Molecular Biology).
The number is a summary, not the whole story. If the score is borderline, look at the trace, not just the digit.
The factors that matter for your experiment
RIN does not exist in isolation. Four properties of your assay change how much degradation you can absorb:
- Amplicon length. Short amplicons (under ~150 bp) are more forgiving. Degradation produces fragments; if your amplicon fits inside surviving fragments, you still amplify. Long amplicons (over ~250 bp) drop out first as integrity falls.
- Target abundance. A high-Ct target near the detection limit has no margin. Degradation costs you the signal entirely. A high-abundance target with Ct in the low 20s tolerates more loss before the result becomes unreliable.
- Reference gene behavior at the same RIN. Normalization rescues some degradation effects — but only if your reference genes degrade at the same rate as your targets. They often do not.
- Sample replaceability. Cell culture you can re-do. Patient biopsies, archived tissue, and field-collected samples you cannot. The cost of "re-extract" sets the bar for "proceed anyway."
Hold those four in mind as you walk the paths below.
Path A — RIN ≥ 8: proceed
This is the easy case. Fleige and Pfaffl recommend RIN above 8 as "perfect total RNA" for downstream applications (Fleige & Pfaffl 2006, Mol Aspects Med). At this integrity, DDCt fold changes are not meaningfully distorted by degradation. Run the assay, normalize, and report the RIN range in your methods.
One caveat: high RIN is necessary but not sufficient. Reference gene stability still depends on biology — treatment, hypoxia, cell cycle. Confirm with GeNorm and NormFinder validation of your reference genes for the conditions you actually ran. RIN 9 with a co-regulated reference pair is still a bad analysis.
Path B — RIN 5–7: conditional proceed
This is where most practitioners actually live. Published cutoffs vary — the literature spans RIN 5 to 8 depending on application. The same Fleige and Pfaffl paper notes that RIN above 5 is acceptable as "good total RNA" for downstream use (Fleige & Pfaffl 2006).
For RT-qPCR specifically, you can usually proceed in this range if you do three things:
- Use short amplicons. Design or pick assays with amplicons under ~150 bp. The shorter the amplicon, the less the partial degradation can corrupt your Ct values. If your assay was designed against a 280 bp amplicon, redesign before you blame the RIN.
- Validate reference genes at this RIN, not at RIN 9. Reference gene stability rankings shift with sample quality. A reference panel that scored M < 0.5 in your fresh-tissue pilot may not be stable across your degraded-archive cohort. Re-run GeNorm and NormFinder on the actual samples.
- Watch for 3′ bias. Random-hexamer reverse transcription on degraded RNA over-represents the 3′ ends of transcripts. If your assay sits 5′ in the gene, you will under-detect. Oligo-dT priming makes this worse. Gene-specific or random-hexamer priming with 3′-anchored amplicons is the safer combination.
And keep RIN consistent across your samples. A study where treatments average RIN 8.5 and controls average RIN 5.5 produces "fold changes" that are partly degradation artifact. Even if you cannot hit RIN 8 across the board, hitting roughly the same RIN across the board is what protects your comparisons.
Path C — RIN below 5 or non-measurable
FFPE and archived clinical samples are a separate world. Formalin-fixed paraffin-embedded RNA is heavily fragmented and chemically modified. The Bioanalyzer often returns a non-measurable RIN or a value below 3 on FFPE samples that still produce usable qPCR data. RIN was developed on fresh-tissue RNA and does not cleanly extend to FFPE. Expect to use degradation-tolerant assay design (very short amplicons, 3′-biased primers) and acknowledge the limitation explicitly in your methods.
If your sample is FFPE, archived clinical material, or fresh tissue at RIN 3, the question shifts from "should I proceed" to "can I make this defensible." Practical moves:
- Drop amplicons to ~70–100 bp.
- Use 3′-biased gene-specific primers; avoid 5′ UTR amplicons.
- Validate reference genes specifically in degraded tissue (GAPDH default is rarely right here).
- State the integrity limitation in the manuscript.
When to not proceed regardless of RIN
Some failures are not rescuable by clever assay design:
- Inconsistent integrity across treatment groups. If treatment samples cluster at RIN 4 and controls cluster at RIN 8, you are measuring degradation, not biology. Re-extract or drop the cohort.
- Evidence of inhibitors. Standard curve slope outside the −3.6 to −3.1 range, or efficiency stuck below 85% on samples that previously hit 95%, points at carryover from extraction. Clean up before you invoke RIN at all.
- Targets at the detection limit. A Ct above 35 on intact RNA is already noisy. The same target on degraded RNA is signal you cannot trust at any RIN.
MIQE 2.0 reporting. The MIQE guidelines — updated to MIQE 2.0 in 2025 — require RNA integrity to be reported in the methods section. Include the method used (RIN, RQI, or equivalent), the instrument, and the values for the sample set. See the original MIQE guidelines (Bustin et al. 2009) and confirm against the MIQE 2.0 checklist before submission. A defensible methods paragraph names the integrity range, the assay design that justified proceeding, and the reference-gene validation. See our MIQE guidelines checklist for the full reporting set.
Summary table
| RIN range | Short amplicon (<150 bp) | Long amplicon (>250 bp) |
|---|---|---|
| ≥ 8 | Proceed | Proceed |
| 5–7 | Proceed with reference-gene re-validation at this RIN | Caution — redesign amplicon or expect distortion |
| < 5 (fresh tissue) | Caution — document limitation, hold RIN consistent across groups | Stop — re-extract |
| FFPE / clinical archive | Proceed with degradation-tolerant design | Stop — redesign required |
| RIN inconsistent across groups | Stop — re-extract; differential degradation produces false fold changes | |
RIN is one input to a broader decision. Amplicon length, reference gene stability, and primer efficiency deserve the same scrutiny. AnnealIQ handles reference-gene validation, primer-efficiency checks, and MIQE-aligned methods text in one workflow. For the analysis decisions that follow this one, see our writeups on calculating primer efficiency from a standard curve and choosing reference genes for qPCR normalization.